Influence of aspirin on pilocarpine-induced epilepsy in mice

Korean Journal of Physiology and Pharmacology

Volumn 17, Issue 1, 2013, Pages 15-21

  Jeong, Kyoung Hoon ^a   Kim, Joo Youn ^a   Choi, Yun Sik ^b   Lee, Mun Yong ^a   Kim, Seong Yun ^a  

^a The Catholic University of Korea   (South Korea)

^b Catholic University of Daegu   (South Korea)

Author keywords

Aspirin; Hippocampus; Mice; Seizure susceptibility; Status epilepticus

Indexed keywords

ACETYLSALICYLIC ACID; PILOCARPINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; EPILEPTIC STATE; IMMUNOHISTOCHEMISTRY; MALE; MORTALITY; MOUSE; NERVE CELL NECROSIS; NEUROPATHOLOGY; NONHUMAN; SEIZURE SUSCEPTIBILITY; TREATMENT DURATION;

EID: 84876759811     PISSN: 12264512     EISSN: 20933827     Source Type: Journal    
DOI: 10.4196/kjpp.2013.17.1.15     Document Type: Article

References (43)

1. Fisher PD, Sperber EF, Moshé SL. Hippocampal sclerosis revisited. Brain Dev. 1998;20:563-573.
2. Shibley H, Smith BN. Pilocarpine-induced status epilepticus results in mossy fiber sprouting and spontaneous seizures in C57BL/6 and CD-1 mice. Epilepsy Res. 2002;49:109-120.
3. Turski WA, Cavalheiro EA, Bortolotto ZA, Mello LM, Schwarz M, Turski L. Seizures produced by pilocarpine in mice: A behavioral, electroencephalographic and morphological analysis. Brain Res. 1984;321:237-253.
4. Parent JM, Lowenstein DH. Seizure-induced neurogenesis: Are more new neurons good for an adult brain? Prog Brain Res. 2002;135:121-131.
5. Buckmaster PS. Laboratory animal models of temporal lobe epilepsy. Comp Med. 2004;54:473-485.
6. Morimoto K, Fahnestock M, Racine RJ. Kindling and status epilepticus models of epilepsy: Rewiring the brain. Prog Neurobiol. 2004;73:1-60.
7. McNamara JO, Huang YZ, Leonard AS. Molecular signaling mechanisms underlying epileptogenesis. Sci STKE. 2006;2006: Re12.
8. Scorza FA, Arida RM, Naffah-Mazzacoratti Mda G, Scerni DA, Calderazzo L, Cavalheiro EA. The pilocarpine model of epilepsy: What have we learned? An Acad Bras Cienc. 2009; 81:345-365.
9. Ravizza T, Balosso S, Vezzani A. Inflammation and prevention of epileptogenesis. Neurosci Lett. 2011;497:223-230.
10. Ravizza T, Gagliardi B, Noé F, Boer K, Aronica E, Vezzani A. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: Evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis. 2008;29:142-160.
11. Lehtimäki KA, Liimatainen S, Peltola J, Arvio M. The serum level of interleukin-6 in patients with intellectual disability and refractory epilepsy. Epilepsy Res. 2011;95:184-187.
12. Libbey JE, Kennett NJ, Wilcox KS, White HS, Fujinami RS. Interleukin-6, produced by resident cells of the central nervous system and infiltrating cells, contributes to the development of seizures following viral infection. J Virol. 2011;85:6913-6922.
13. Auvin S, Mazarati A, Shin D, Sankar R. Inflammation enhances epileptogenesis in the developing rat brain. Neurobiol Dis. 2010;40:303-310.
14. Pitkänen A. Therapeutic approaches to epileptogenesis-hope on the horizon. Epilepsia. 2010;51 Suppl 3:2-17.
15. Pitkänen A, Lukasiuk K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol. 2011;10:173-186.
16. Löscher W, Brandt C. Prevention or modification of epileptogenesis after brain insults: Experimental approaches and translational research. Pharmacol Rev. 2010;62:668-700.
17. Amann R, Peskar BA. Anti-inflammatory effects of aspirin and sodium salicylate. Eur J Pharmacol. 2002;447:1-9.
18. Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE 3rd, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983;309:396-403.
19. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol. 2012;9:259-267.
20. Bernheisel CR, Schlaudecker JD, Leopold K. Subacute management of ischemic stroke. Am Fam Physician. 2011;84:1383-1388.
21. Ikonomidou-Turski C, Cavalheiro EA, Turski L, Bortolotto ZA, Kleinrok Z, Calderazzo-Filho LS, Turski WA. Differential effects of non-steroidal anti-inflammatory drugs on seizures produced by pilocarpine in rats. Brain Res. 1988;462:275-285.
22. Najbauer J, Schuman EM, Mamelak AN. The aspirin metabolite sodium salicylate causes focal cerebral hemorrhage and cell death in rats with kainic acid-induced seizures. Neuroscience. 2000;99:107-117.
23. Ma L, Cui XL, Wang Y, Li XW, Yang F, Wei D, Jiang W. Aspirin attenuates spontaneous recurrent seizures and inhibits hippocampal neuronal loss, mossy fiber sprouting and aberrant neurogenesis following pilocarpine-induced status epilepticus in rats. Brain Res. 2012;1469:103-113.
24. Tandon M, Anuradha K, Pandhi P. Evaluation of antiepileptic activity of aspirin in combination with newer antiepileptic lamotrigine in mice. Methods Find Exp Clin Pharmacol. 2003; 25:607-610.
25. Mordenti J, Chappell W. The use of interspecies scaling in toxicokinetics. In: Yacobi A, Skelly JP, Batra VK, eds. Toxicokinetics and New Drug Development. New York: Pergamon Press; 1989. p.42-96.
26. Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol. 1972;32:281-294.
27. Franklin KBJ, Paxinos G. The Mouse Brain in Stereotaxic coordinates. San Diego: Academic Press; 2001.
28. Borges K, Gearing M, McDermott DL, Smith AB, Almonte AG, Wainer BH, Dingledine R. Neuronal and glial pathological changes during epileptogenesis in the mouse pilocarpine model. Exp Neurol. 2003;182:21-34.
29. Stoll G, Jander S, Schroeter M. Inflammation and glial responses in ischemic brain lesions. Prog Neurobiol. 1998;56: 149-71.
30. Bruke A, Smyth EM, FitzGerald GA. Analgesic-Antipyretic Agents; Pharmacotherapy of Goat. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006. p.671-715.
31. Schubert TA. Salicylate-induced seizures in a dog. J Am Vet Med Assoc. 1984;185:1000-1001.
32. Chen CS, Aberdeen GC. Potentiation of acoustic-traumainduced audiogenic seizure susceptibility by salicylates in mice. Experientia. 1980;36:330-331.
33. Sánchez-Hernandez MC, Delgado J, Navarro AM, Orta JC, Hernandez M, Conde J. Seizures induced by NSAID. Allergy. 1999;54:90-91.
34. Senol N, Ceyhan BM, Ersoy IH, Senol A, Acarturk G, Sutcu R. Aspirin increases NMDA receptor subunit 2A concentrations in rat hippocampus. J Recept Signal Transduct Res. 2012; 32:17-21.
35. Croucher MJ, Collins JF, Meldrum BS. Anticonvulsant action of excitatory amino acid antagonists. Science. 1982;216: 899-901.
36. Bengzon J, Okabe S, Lindvall O, McKay RD. Suppression of epileptogenesis by modification of N-methyl-D-aspartate recep tor subunit composition. Eur J Neurosci. 1999;11:916-922.
37. Chen Q, He S, Hu XL, Yu J, Zhou Y, Zheng J, Zhang S, Zhang C, Duan WH, Xiong ZQ. Differential roles of NR2A-and NR2B-containing NMDA receptors in activity-dependent brainderived neurotrophic factor gene regulation and limbic epileptogenesis. J Neurosci. 2007;27:542-552.
38. Wang SJ. Facilitatory effect of aspirin on glutamate release from rat hippocampal nerve terminals: Involvement of protein kinase C pathway. Neurochem Int. 2006;48:181-190.
39. Lu YG, Tang ZQ, Ye ZY, Wang HT, Huang YN, Zhou KQ, Zhang M, Xu TL, Chen L. Salicylate, an aspirin metabolite, specifically inhibits the current mediated by glycine receptors containing alpha1-subunits. Br J Pharmacol. 2009;157:1514-1522.
40. Holtman L, van Vliet EA, Edelbroek PM, Aronica E, Gorter JA. Cox-2 inhibition can lead to adverse effects in a rat model for temporal lobe epilepsy. Epilepsy Res. 2010;91:49-56.
41. Baik EJ, Kim EJ, Lee SH, Moon C. Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. Brain Res. 1999;843:118-129.
42. Jung KH, Chu K, Lee ST, Kim J, Sinn DI, Kim JM, Park DK, Lee JJ, Kim SU, Kim M, Lee SK, Roh JK. Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Neurobiol Dis. 2006;23:237-246.
43. Polascheck N, Bankstahl M, Löscher W. The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy. Exp Neurol. 2010;224:219-233.